Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Hydrocodone | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Magnesium sulfate | The therapeutic efficacy of Ethyl loflazepate can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Ethyl loflazepate may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Mirtazapine | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Orphenadrine | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Pramipexole | Ethyl loflazepate may increase the sedative activities of Pramipexole. |
| Ropinirole | Ethyl loflazepate may increase the sedative activities of Ropinirole. |
| Rotigotine | Ethyl loflazepate may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethyl loflazepate. |
| Suvorexant | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Thalidomide | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Clozapine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clozapine. |
| Methadone | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Methadone. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Ethyl loflazepate. |
| Phenytoin | The serum concentration of Phenytoin can be increased when it is combined with Ethyl loflazepate. |
| Fosphenytoin | The serum concentration of Fosphenytoin can be increased when it is combined with Ethyl loflazepate. |
| Sodium oxybate | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Teduglutide | The serum concentration of Ethyl loflazepate can be increased when it is combined with Teduglutide. |
| Yohimbine | The therapeutic efficacy of Ethyl loflazepate can be increased when used in combination with Yohimbine. |
| Ethanol | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Zimelidine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Ethyl loflazepate. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Ethyl loflazepate. |
| Zopiclone | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zopiclone. |
| Caffeine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Caffeine. |
| Theophylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Theophylline. |
| Dyphylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Dyphylline. |
| Pentoxifylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Pentoxifylline. |
| Mercaptopurine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Mercaptopurine. |
| Aminophylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Aminophylline. |
| Oxtriphylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Oxtriphylline. |
| Theobromine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Theobromine. |
| Fenethylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Fenethylline. |
| 8-azaguanine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with 8-azaguanine. |
| 7,9-Dimethylguanine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with 7,9-Dimethylguanine. |
| Xanthine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Xanthine. |
| 7-Deazaguanine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with 7-Deazaguanine. |
| Guanine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Guanine. |
| 9-Methylguanine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with 9-Methylguanine. |
| Peldesine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Peldesine. |
| Hypoxanthine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Hypoxanthine. |
| 9-Deazaguanine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with 9-Deazaguanine. |
| Propentofylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Propentofylline. |
| Valomaciclovir | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Valomaciclovir. |
| 3-isobutyl-1-methyl-7H-xanthine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine. |
| Uric acid | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Uric acid. |
| Doxofylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Doxofylline. |
| 6-O-benzylguanine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with 6-O-benzylguanine. |
| Lisofylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Lisofylline. |
| Lobucavir | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Lobucavir. |
| Cafedrine | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Cafedrine. |
| Theodrenaline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Theodrenaline. |
| Bamifylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Bamifylline. |
| Proxyphylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Proxyphylline. |
| Acefylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Acefylline. |
| Etamiphylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Etamiphylline. |
| Pentifylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Pentifylline. |
| Bufylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Bufylline. |
| Bromotheophylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Bromotheophylline. |
| Furafylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Furafylline. |
| 8-chlorotheophylline | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with 8-chlorotheophylline. |
| PCS-499 | The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with PCS-499. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Ethyl loflazepate. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Ethyl loflazepate. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Ethyl loflazepate. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Ethyl loflazepate. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Ethyl loflazepate. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Ethyl loflazepate. |